login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
KIROMIC BIOPHARMA INC (KRBP) Stock News
USA
- NASDAQ:KRBP -
US4976342042
-
Common Stock
1.45
USD
-0.13 (-8.23%)
Last: 9/13/2023, 8:21:06 PM
0.6931
USD
-0.76 (-52.2%)
After Hours:
9/13/2023, 8:21:06 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
KRBP Latest News, Press Relases and Analysis
All
Press Releases
8 months ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
9 months ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01
10 months ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
a year ago - By: InvestorPlace
KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q2 2024
a year ago - By: BusinessInsider
KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024
a year ago - By: InvestorPlace
KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024
10 months ago - By: Benzinga
Financial Crime Weekly: CEO Sentenced To 51 Months In Prison, Kiromic BioPharma Charged With Failure To Disclose Material Information
10 months ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation
a year ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01
a year ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial
a year ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
a year ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation
a year ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation
a year ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
a year ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01
a year ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase
a year ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
a year ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
a year ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
a year ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
a year ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
2 years ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
2 years ago - By: Kiromic BioPharma, Inc.
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
2 years ago - By: Virtual Investor Conferences
- Mentions:
LSTA
SYRA
ACHV
MRDH
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
2 years ago - By: Virtual Investor Conferences
- Mentions:
LSTA
SYRA
ACHV
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
2 years ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
2 years ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
2 years ago - By: Virtual Investor Conferences
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
2 years ago - By: Kiromic BioPharma, Inc.
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
2 years ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
2 years ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
2 years ago - By: Kiromic BioPharma, Inc.
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
2 years ago - By: Kiromic BioPharma, Inc.
- Mentions:
OTC
Kiromic BioPharma Announces Uplisting to OTCQB Market
2 years ago - By: Kiromic BioPharma, Inc.
- Mentions:
OTC
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
2 years ago - By: Kiromic BioPharma, Inc.
- Mentions:
OTC
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
2 years ago - By: Benzinga
- Mentions:
INFI
SCNI
NSTG
JYNT
...
12 Health Care Stocks Moving In Wednesday's After-Market Session
2 years ago - By: Seeking Alpha
Kiromic BioPharma to list on OTC Pink Sheets after Nasdaq trading suspension (NASDAQ:KRBP)
2 years ago - By: Kiromic BioPharma
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
Please enable JavaScript to continue using this application.